GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

Laurence Booth¹, Cameron West², Daniel Von Hoff³ and Paul Dent¹

¹ Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, United States, ²Genzada Pharmaceuticals, Sterling, KS, United States, ³Translational Genomics Research Institute (TGEN), Phoenix, AZ, United States

GZ17-6.02 (602) is presently under phase I clinical evaluation (NCT03775525). We defined the mechanisms by which it interacted with a standard of care therapeutic doxorubicin to kill sarcoma cells. Doxorubicin and 602 interacted to rapidly activate ATM and c-MET, inactivate mTOR, AKT, and p70 S6K, enhance the expression of Beclin1 and reduce the levels of K-RAS and N-RAS. This was followed later by the drugs interacting to reduce expression of MCL-1, BCL-XL, and HDAC6. Knock down of ATM prevented the drugs alone or in combination inactivating mTOR or activating ULK1. Knock down of c-MET significantly enhanced [doxorubicin + 602] lethality. Knock down of ATM and to a greater extent ULK1, Beclin1, or ATG5 significantly reduced killing by 602 alone or when combined with doxorubicin. Expression of an activated mTOR mutant suppressed killing, autophagosome formation and prevented autophagic flux. In the absence of Beclin1, knock down of CD95, or FADD, or over-expression of c-FLIP-s or BCL-XL abolished tumor cell killing. We conclude that 602 and doxorubicin interact to increase autophagosome formation and autophagic flux as well as causing elevated death receptor signaling resulting in mitochondrial dysfunction and tumor cell death.

Keywords: autophagy, GZ17-6.02, sarcoma, doxorubicin, CD95, death receptor

INTRODUCTION

GZ17-6.02 (602) comprises of three natural products, curcumin, isovanillin, and harmine (1, 2). In our most recent studies in eight gastrointestinal tumor cell lines we determined that low concentrations of 602 killed tumor cells and interacted with a standard of care drug for these tumor types, 5-fluorouracil (5FU), to further enhance tumor cell death (2). GZ17-6.02 activated an ATM-AMPK signaling module which was responsible for inactivation of mTORC1 and mTORC2, dephosphorylation of ULK1 S757, and increased phosphorylation of ULK1 S317 and of ATG13 S318. Autophagosome formation and autophagic flux were observed. GZ17-6.02 and 5FU caused greater ATM activation, more autophagosome formation and more tumor cell killing; knock down of ULK1, Beclin1, or ATG5 suppressed the lethality of 602 alone and when in combination with 5FU. Exposure of CT26 mouse colorectal tumors to 602 and 5FU prolonged animal survival.

Sarcomas are a diverse set of malignancies originating from mesenchymal cells and these malignancies are approximately one percent of diagnosed human tumors (3, 4). There are two major groups of sarcomas, bone sarcomas and soft tissue sarcomas (STS). Approximately twelve thousand Americans will be diagnosed with a sarcoma in 2020 with ~60% of patients receiving curative surgery and chemo-radiotherapy (5). For the thirty to forty percent of patients whose...
disease has spread, the majority will ultimately die, despite utilization of the most up-to-date therapeutic modalities. In the past 5 years the multi-kinase and chaperone inhibitor pazopanib was FDA approved for treatment of the majority of STS subtypes (6). Pazopanib, alone or in combination with other agents in our hands utilizes endoplasmic reticulum stress signaling and autophagosome formation as key components of its mechanisms of action (7–10). In preliminary studies for this manuscript initially we examined whether pazopanib and 602 could interact to kill sarcoma cells. To our surprise, pazopanib and 602 did not interact, with the drug combination causing only approximately a twenty percent increase in killing over either agent individually. Prior to the approval of pazopanib, STS was treated with a variety of well-established cytotoxic chemotherapy regimens, including doxorubicin (11, 12). In further preliminary studies 602 and doxorubicin interacted in an additive to greater than additive fashion to kill STS cells. The present manuscript set out to define the molecular mechanisms by which 602 and doxorubicin interact to kill STS cells.

**MATERIALS AND METHODS**

**Materials**

Doxorubicin was purchased from Selleckchem (Houston, TX). GZ17-6.02 was supplied by Genzada Pharmaceuticals Inc. (Sterling, KS). The human sarcoma cell lines HT1080 and MES-SA were obtained from the ATCC (Bethesda, MD) and were not further validated beyond that provided by the vendor. Trypsin-EDTA, DMEM, RPMI, penicillin-streptomycin were purchased from GIBCOBRL (GIBCOBRL Life Technologies, Grand Island, NY). Plasmids were purchased from Addgene, (Cambridge, MA). Commercially available validated short hairpin RNA molecules to knock down RNA/protein levels were from Qiagen (Valencia, CA). The pre-validated smart-pool siRNA molecules used were: siSCR (SI03650318), cathepsin B (1027416), BAX (GS5562), BAD (GS8678), Beclin1 (3495), FADD (GS8772), P-AMPKα (5324), ATG5 (12994), CD95 (GS5562), AIF (GS9131), ELF2α (GS83939), FADD (GS8772), ULK-1 (GS8408), ATG13 (GS9776). The antibodies used in these studies were: AIF (5318), BAX (5023), BAD (12105), BAD (9239), BIM (2933), BAK1 (12105), Beclin1 (3495), cathepsin B (31718), CD95 (8023), FADD (2782), ELF2α (5324), P-ELF2α S51 (3398), ULK-1 (8054), ULK-1 S757 (14202), P-AMPKα T172 (2535), P-AMPKα (2532), P-ATM S198 (13050), ATM (2873), ATG5 (12994), mTOR (2873), P-mTOR S2481 (5536), P-mTOR S2448 (5536), P-STAT3 Y705 (9145), P-p65 NFκB S536 (3033), P-p65 (23214), LAMP2 (49067) all from Cell Signaling Technology; P-ULK-1 S317 (3803a) from Abgent; P-ATG13 S318 (19127) from Novus Biologicals. Antibodies directed against RAS proteins: ThermoFisher (Waltham MA) N-RAS PA5-14833; K-RAS PA5-44339. Control studies are presented showing on-target specificity of antibodies to detect total protein levels and phosphorylated levels of proteins (Supplementary Figures 1, 2).

**Methods**

**Culture, Transfection, and in vitro Exposure of Cells to Drugs**

All cell lines were cultured at 37°C (5% (v/v) CO2) in vitro using RPMI supplemented with 5% (v/v) fetal calf serum and 10% (v/v) non-essential amino acids. Cells were transfected with siRNA molecules or plasmids as described in prior manuscripts (7–10). Cells were transfected with plasmids (0.1 μg) using lipofectamine 2000. Representative data sets showing protein knock down or over-expression are presented in Supplementary Figures 1, 2.

**Detection of Cell Death by Trypan Blue**

Trypan blue exclusion was used to assess cell viability at each experimental time point. Floating cells were isolated along with attached cells that were harvested by trypsinization with Trypсин/EDTA for ~3 min at 37°C. Following isolation, the total cell population for each experimental point was assessed for cell viability.

**Colony Formation Assays**

Single cells were plated into 60 mm dishes (500/dish). Twelve hour after plating cells were treated with vehicle control, 602 (0.5–2 μM), doxorubicin (0.5–2 μM) or the drugs in combination at a fixed dose ratio. Twenty-four hour after drug exposure, the growth media was removed, cells washed with drug free media and then cells were cultured for an additional 7 days in drug free media. Cells were fixed in place, stained with crystal violet and the number of colonies, a group of > 50 cells, counted. The synergy of drug interaction was determined via the Method of Cho and Tallalay using Calcusyn for Windows program.

**Detection of Protein Expression and Protein Phosphorylation by In-Cell Western Blotting Using a Hermes WiScan Microscope**

The Hermes WiScan wide field microscope (https://idea-bio.com/products/wiscan-hermes/). The machine combines high quality optics with a high-quality computer driven microscope stage, and with dedicated software, for example, to analyze the immunofluorescent staining intensity of individual cells, i.e., true in-cell western blotting. Cells (4 × 103) were plated into 96-well plates and allowed to grow over night. A typical experiment proceeds thus: three independent thaw/cultures of a particular tumor cell type are sub-cultured into individual 96-well plates. Twenty-four hour after plating, the cells are transfected with a control plasmid or a control siRNA, or with plasmids to express various proteins or validated siRNA molecules to knock down the expression of various proteins. After another 24 h, the cells are ready for drug exposure(s). At various time-points after the initiation of
drug exposure, cells are fixed in place with permeabilization. Standard immunofluorescent blocking procedures are employed, followed by incubation of different wells with a variety of validated primary antibodies. The next morning, after washing, fluorescent-tagged secondary antibodies are added to each well; in general, we have found that using more than two tagged antibodies in each well results in poorer data/image quality. After 3 h of incubation, the secondary antibody is removed, the cells washed again, and are hydrated with phosphate buffered saline prior to microscopic examination. Based on the experiment, cells are visualized at either 10X magnification for bulk assessments of immunofluorescent staining intensity or at 60X magnification for assessments of protein or protein–protein colocalization.

For studies at 10X magnification, the operator selects which fluorescent antibody will be assessed first, i.e., in the red or green channel, and then focuses the microscope in a vehicle control transfection control well. The operator then outlines for the computer controlling the microscope “what is a cell.” In other words, the operator manually inputs the criteria for each specific tumor cell line segregating away detection of what is obvious debris or a staining artifact. The operator then sets how many cells per well are to be assessed for their immunofluorescent staining intensity; 100. The computer/microscope then determines the background fluorescence in the well and in parallel randomly determines the mean fluorescent intensity of those 100 cells; the operator is provided with this mean intensity value. Of note for scientific rigor is that the operator does not personally manipulate the microscope to examine specific cells; the entire fluorescent accrual method is independent of the operator. Once the entire plate has been scanned for one of the secondary antibodies, the second secondary antibody with a different fluorescence range has been obtained, the second and third sets of independent cultures, with an independent total of 300 cells under each condition being assessed (+/- SD).

**Data Analysis**

Comparison of the effects of various treatments (in independent triplicate three times) was using one-way ANOVA and a two-tailed Student's t-test. Differences with a $p < 0.05$ were considered statistically significant. Experiments are the means of multiple individual points from multiple experiments (± SD).

**RESULTS**

**GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells**

Our preliminary studies demonstrated that GZ17-6.02 (602) interacted with doxorubicin to kill HT1080 cells (Figure 1A). Exposure of MES cells to 602 alone caused a similar amount of tumor cell death when compared to prior studies in GI tumor cells, whereas HT1080 cells appeared to be more sensitive (2). In colony formation assays 602 and doxorubicin synergized to kill sarcoma cells with combination index values below ~1.0 (Figure 1B).

**GZ17-6.02 and Doxorubicin Interact to Activate ATM, Inactivate AKT and mTOR, and Reduce RAS Protein Levels, Concomitant With Activating Cyto-Protective c-MET**

We next defined the impact of 602 in the presence or absence of doxorubicin on cellular signaling processes. As a single agent over a 6-h time course, 602 activated ataxia telangietasia mutated (ATM), the AMP-dependent protein kinase (AMPK), ULK1, inhibited mTORC1, mTORC2 and eIF2α, and increased ATG13 S318 phosphorylation (Figures 2, 3; Supplementary Figure 3). Most obviously, at the 3-h timepoint, 602 and doxorubicin interacted in a greater than additive fashion to: activate ATM; inactivate AKT, p70 S6K, JNK1/2, mTORC1, mTORC2, and STAT5; increase Beclin1 expression and reduce the levels of HDAC6, K-RAS, and N-RAS; and activate the receptor tyrosine kinase c-MET (Figure 4; Supplementary Figure 4). Knock down of the hepatocyte growth factor receptor, c-MET, significantly enhanced the lethality of [602 + doxorubicin] in sarcoma cells, arguing that the immediate-early activation of this receptor tyrosine kinase was a compensatory survival signal (Supplementary Figure 5). There are at present multiple small molecule agents/drugs that have been developed to inhibit c-MET, including crizotinib (XALKORI®) that is FDA approved for the treatment of ALK or ROS1 mutant expressing non-small cell lung cancer. We determined whether any c-MET inhibitor could enhance [602 + doxorubicin] lethality (Supplementary Figure 6). The standard care sarcoma drug pazopanib was toxic as a single agent and enhanced the lethality of [602 + doxorubicin]. The c-MET inhibitors crizotinib, foretinib, BMS-777607 and tivantinib all also enhanced basal levels of tumor cell death and enhanced [602 + doxorubicin] lethality.

**Cyto-Protective Activation of c-MET Requires Its Ligand HGF**

In prior radiation oncology-based studies we have demonstrated that ionizing radiation, in carcinoma cells, causes two waves of ERBB1 and ERK1/2 activation, the second wave being caused by autocrine TGFα signaling (13–15). As we observed [602 + doxorubicin] causing activation of c-MET, we hypothesized that the ligand for this receptor, hepatocyte growth factor (HGF), may be playing a role in the receptor’s compensatory survival signal. Cells were exposed to [602 + doxorubicin] in the presence of a control antibody or an antibody to neutralize HGF. Antibody-based neutralization of HGF function prevented the drug-induced activation of c-MET (Supplementary Figures 7, 8).
FIGURE 1 | GZ17-6.02 and doxorubicin interact to kill sarcoma cells. (A) HT1080 and MES human sarcoma cells were treated with vehicle control, GZ17-6.02 (2 µM final curcumin), doxorubicin (200 nM) or the drugs in combination for 12-24 h. Cells were isolated, and viability determined by a trypan blue exclusion assay (n = 3 +/− SD). # p < 0.05 greater than either 602 or doxorubicin alone. (B) Single cells were plated into 60 mm dishes (500/dish, six separate dishes from two independent thawed cell vials). Twelve hour after plating cells were treated with vehicle control, 602 (0.5–2.0 µM), doxorubicin (0.5–2.0 µM) or the drugs in combination at a fixed dose ratio. Twenty-four hour after drug exposure, the growth media was removed, cells washed with drug free media and then cells were cultured for an additional 7 days in drug free media. Cells were fixed in place, stained with crystal violet and the number of colonies, a group of >50 cells, counted. The synergy of drug interaction was determined via the Method of Cho and Tallay using CalcuSyn for Windows program. A combination index (CI) value of <1.0 is considered synergistic.

GZ17-6.02 and Doxorubicin Interact to Kill via Activation of ATM-AMPK-ULK1-Autophagy

Our cell signaling data with 602 and doxorubicin in sarcoma cells was similar, though not identical, to our prior work with 602 in GI tumor cells (2). Knock down of ATM prevented the drug combination from activating the AMPK and ULK1, inactivating mTORC1 or increasing ATG13 S318 phosphorylation (Supplementary Figure 9). Knock down of either ATM or AMPKα significantly reduced the lethality of 602 as a single agent and when it was combined with doxorubicin (Figure 5). Knock down of Beclin1 or ATG5, and in one cell line ULK1, suppressed killing to a greater extent than observed in ATM/AMPKα knock down cells. This data collectively tends to emphasize the importance of “autophagy” in the lethality of [602 + doxorubicin].

GZ17-6.02 and Doxorubicin Interact to Cause Toxic Autophagic Flux

The kinase mTOR is a key gate-keeper regulator and signal integrator controlling the formation of autophagosomes. Expression of an activated mutant form of mTOR significantly reduced the lethality of 602, doxorubicin and the drug combination, though the effect was less dramatic than observed for knocking down Beclin1 or ATG5 (Figure 6A; Supplementary Figure 10). We then determined the impact of activated mTOR on the ability of cells to form autophagosomes and exhibit autophagic flux. Doxorubicin and 602 combined in an at least additive fashion to cause GFP+ autophagosome formation within 4 h with no alteration in RFP+ autolysosome formation (Figure 6B; Supplementary Figure 10). Eight hours after drug exposure, the numbers of GFP+ autophagosome levels declined and those of RFP+ autolysosome formation had increased. This implies autophagic flux had occurred. In cells expressing activated mTOR, the formation of autophagosomes after 4 h was reduced compare to empty vector transfected cells. And, after 8 h, no statistically significant increase in autolysosome levels was observed, despite autophagosome levels declining. Collectively, our data argue that the expression of autophagy regulatory proteins, Beclin1 and ATG5, together with inactivation of mTOR, play key roles in mediating at least fifty percent of the anti-cancer actions of [602 + doxorubicin].

GZ17-6.02 and Doxorubicin Interact to Cause Toxic Death Receptor Signaling

We next wished to determine the additional autophagy-independent mechanisms that [602 + doxorubicin] recruit to kill sarcoma cells. In cells with the expression of Beclin1 transiently reduced, knock down of CD95, FADD, or RIP1 almost abolished
tumor cell killing (Figure 7A; Supplementary Figure 11). Previously, we had shown that knock down of c-MET enhanced [602 + doxorubicin] lethality; however, knock down of c-MET in the absence of Beclin1 did not increase killing arguing that activation of c-MET protects cells by trying to restrain autophagy. Over-expression of the caspase 8 inhibitor c-FLIP-s, the mitochondrial protective protein BCL-XL or a dominant negative form of caspase 9 also virtually abolished drug toxicity when Beclin1 expression was knocked down (Figure 7B; Supplementary Figure 11). Thus, there are two major components of cell killing, one requiring autophagy and the other death receptor signaling. Data in Figure 5 shows us that knock down of Beclin1 or ATG5 is strongly protective. Our published data has shown that 602 uses death receptor signaling as a key component of the killing process and data in Figure 7 shows us that the majority of the killing caused by the [602 + doxorubicin] combination is prevented by knock down of Beclin1 combined with interdiction of CD95 death receptor signaling. Hence, the two most important mechanisms by which 602 and doxorubicin combine to kill sarcoma cells are via autophagosome formation and activation of death receptors.

GZ17-6.02 Reduced the Expression of HDAC Proteins and Alters Their Sub-cellular Localization

It has been argued that 602 directly alters tumor cell biology via the regulation of super-enhancer elements (16). Exposure of sarcoma cells to 602 for 1 h reduced the expression of histone deacetylases (HDACs) 1–11, an effect which was prevented by knock down of Beclin1 (Figure 8). HDAC proteins can be phosphorylated by the AMPK which alters their sub-cellular localization; phosphorylated HDACs leave the nucleus (17–19). In sarcoma cells, a 1 h 602 exposure caused increased phosphorylation of the conserved phosphorylation site in HDACs4/5/7, an effect which required expression of AMPKα (Figure 9A). This was associated with the significant majority of HDACs4/5/7 concentrating in the nucleus (Figure 9B; *p < 0.05). HDACs1/8/9/10/11 under basal conditions were all localized in the nucleus (Figure 10). After treatment of cells with 602, HDACs1/8/10 exited the nucleus, however, the localization of HDACs9/11 was not changed (19). Knock down of AMPKα prevented 602 from translocating HDACs1/8/10 out of the nucleus (Figure 11). Thus, in sarcoma cells, AMPK signaling caused by 602 exposure regulates HDAC degradation, HDAC nuclear entry and HDAC nuclear exit.

DISCUSSION

The present studies were performed to determine the biology of sarcoma cells when exposed to GZ17-6.02. GZ17-6.02 as a single agent caused tumor cell death to a similar degree as was previously noted in GI tumor cells, and when 602 was combined with a former standard of care agent for the treatment of sarcoma, doxorubicin, additional cell killing was observed (2).
FIGURE 4 | GZ17-6.02 and doxorubicin interact to activate c-MET. HT1080 human sarcoma cells were treated with vehicle control, GZ17-6.02 (2 \( \mu \)M final curcumin), doxorubicin (200 nM) or the drugs in combination for 3 and 6 h. Cells were fixed in place and immunostained to detect the total expression and the total phosphorylation of the indicated proteins. The phosphorylation of each phosphoprotein was corrected for total protein expression; HDAC6 had its expression corrected using invariant ERK2 expression. (\( n = 3 \) +/- SD) *\( p < 0.05 \) less than vehicle control; #\( p < 0.05 \) greater than vehicle control.

FIGURE 5 | GZ17-6.02 and doxorubicin individual and combination lethality is suppressed by knock down of ULK1, Beclin1, or ATG5. HT1080 and MES human sarcoma cells were transfected with a scrambled siRNA control (siSCR) or siRNA molecules to knock down the indicated proteins. Twenty-four hour afterwards, cells treated with vehicle control, GZ17-6.02 (2 \( \mu \)M final curcumin), doxorubicin (200 nM) or the drugs in combination for 12 h. Cells were isolated, and viability determined by a trypan blue exclusion assay (\( n = 3 \) +/- SD). *\( p < 0.05 \) less than vehicle control; **\( p < 0.05 \) less than corresponding value in siATM or siAMPK\( \alpha \) transfected cells.

The drugs combined to activate an ATM-AMPK-ULK1-autophagy pathway, also inactivating AKT and mTOR, but surprisingly also activating the receptor tyrosine kinase c-MET. Knock down of c-MET or use of c-MET small molecule inhibitors significantly enhanced [602 + doxorubicin] lethality demonstrating that this rapid activation of c-MET was a compensatory survival signal. Activation of c-MET required autocrine signaling by its ligand HGF. Previously, in sarcoma cells treated with the multi-kinase inhibitor pazopanib and the HDAC inhibitors sodium valproate or entinostat we also observed, in drug-resistant cells, that c-MET as well as ERBB1 had become activated (10). Use of the multi-kinase inhibitor neratinib reduced the protein levels of both receptors and significantly enhanced [pazopanib + entinostat] lethality. In colon cancer cells and tumors previously exposed to curcumin combined with sildenafil we discovered that the cells had evolved to express higher levels of PDGF\( \beta \) phosphorylation in the tumor cells (20, 21). Inhibition of PDGF\( \beta \) signaling via siRNA knock down or using the standard of care drug regorafenib restored the efficacy of the curcumin sildenafil combination. In the studies with pazopanib, entinostat and neratinib, one essential process for efficient tumor cell killing was autophagosome formation and autophagic flux (10). In our
Expression of activated mTOR suppresses tumor cell killing and abolishes autophagic flux.

(A) HT1080 human sarcoma cells were transfected with an empty vector plasmid (CMV) or with a plasmid to express a mutant active mTOR protein. Twenty-four hour afterwards, cells treated with vehicle control, GZ17-6.02 (2 µM final curcumin), doxorubicin (200 nM) or the drugs in combination for 12 h. Cells were isolated, and viability determined by a trypan blue exclusion assay (n = 3 +/-SD). *p < 0.05 less than vehicle control.

(B) HT1080 cells were transfected with an empty vector plasmid (CMV) or with a plasmid to express a mutant active mTOR protein and in parallel all transfected with a plasmid to express LC3-GFP-RFP. Twenty-four hour afterwards, cells treated with vehicle control, GZ17-6.02 (2 µM final curcumin), doxorubicin (200 nM) or the drugs in combination for 4 or 8 h. At each time point the mean number of intense GFP+ and RFP+ vesicles was determined counting > 40 cells per condition. (n = 3 +/-SD) #p < 0.05 greater than corresponding values after 4 h; ¶p < 0.05 less than corresponding values after 4 h; §p < 0.05 less than corresponding values in CMV transfected cells.

In the absence of autophagy, GZ17-6.02-induced killing is mediated via CD95-FADD.

(A) HT1080 human sarcoma cells were transfected with a scrambled siRNA (siSCR) or with an siRNA to knock down the expression of Beclin1, and in parallel, siBeclin1 transfected cells were transfected to knock down the expression of the indicated proteins. Twenty-four hour afterwards, cells treated with vehicle control or with [GZ17-6.02 (2 µM final curcumin) + doxorubicin (200 nM)] in combination for 12 h. Cells were isolated, and viability determined by a trypan blue exclusion assay (n = 3 +/-SD). *p < 0.05 less than vehicle control; **p < 0.05 less than corresponding value in siBeclin1 alone.

(B) HT1080 cells were transfected with a scrambled siRNA (siSCR) or with an siRNA to knock down the expression of Beclin1, and in parallel, cells were transfected with an empty vector plasmid or with plasmids to express BCL-XL, c-FLIP-s or dominant negative caspase 9. Twenty-four hour afterwards, cells treated with vehicle control or with [GZ17-6.02 (2 µM final curcumin) + doxorubicin (200 nM)] in combination for 12 h. Cells were isolated, and viability determined by a trypan blue exclusion assay (n = 3 +/-SD). *p < 0.05 less than vehicle control; **p < 0.05 less than corresponding value in siBeclin1 alone.

In the present studies with 602 and doxorubicin, the drugs combined to cause greater expression of Beclin1 and to reduce mTORC1 and mTORC2 activities. This was associated with an additive to greater than additive increase in autophagosome levels and with greater autophagic flux. Expression of activated mTOR abolished autophagic flux and significantly reduced the lethality.

Frontiers in Oncology | www.frontiersin.org 7 September 2020 | Volume 10 | Article 1331
of either drug alone or in combination. In a delayed fashion, the drugs interacted to reduce expression of MCL-1, BCL-XL, and HDAC6. Reduced HDAC6 expression will result in higher levels of acetylated and inactive HSP90; HSP90 acts as a chaperone for many proteins including ERBB1 and BCL-XL. Knock down of ATM prevented the drugs alone or in combination inactivating mTOR or activating ULK1. Knock down of ATM and to a greater extent ULK1, Beclin1, or ATG5 significantly reduced killing by 602 alone or when combined with doxorubicin. This strongly suggests that activation of ATM plays a critical role in mediating the biological actions of 602 in sarcoma. Expression of an activated mTOR mutant suppressed killing, autophagosome formation and prevented autophagic flux. In the absence of Beclin1, knock down of CD95 or FADD, or over-expression of c-FLIP-s or BCL-XL abolished tumor cell killing. Thus, we have defined the two key mechanisms, autophagy and death receptor signaling, by which 602 alone or in combination with doxorubicin kills sarcoma cells.

In prior studies using combinations of “targeted agents” such as neratinib, afatinib, HDAC inhibitors, sorafenib, and pemetrexed, we were able to demonstrate that cells evolved to express activated growth factor receptors including ERBB1, ERBB3, c-KIT, c-MET, and PDGFRβ. However, in those studies, the altered / evolved signaling parameters were observed days and weeks following drug exposure, not within several hours as in our present work. In the present studies we are using a topoisomerase poison (doxorubicin) and 602 contains the chemical harmine. Harmine is a putative DNA damaging agent and has been proposed to inhibit the relaxation activity of DNA topoisomerase I and II, and inhibit drug efflux pumps. In Saccharomyces cerevisiae harmine caused crossing-over and frameshift mutations. Yeast mutants that were defective in nucleotide excision repair, in error-prone repair and in recombinational repair all exhibited enhanced sensitivity after exposure to harmine, with double mutants of Rad1/Rad6 showing that NER and error-prone repair are independently involved in repair of harmine-induced DNA.
lesions. Harmine can elevate micronuclei levels in eukaryotic cells and in the Ames test, harmine could induce frameshift mutations in S. typhimurium strains TA97 and TA98 (28). Thus, the cellular response to 602 and doxorubicin will be the sensing and the outcomes of multiple different forms of DNA damage.

GZ17-6.02 has been argued to regulate super-enhancer regions in the genome which drive a high level of transcription of transcriptional regulatory proteins (16). The authors in reference 16 observed reduced Histone 3 K27 acetylation 24–72 h after 602 exposure. In the present studies, at much earlier time points, we found that 602 rapidly caused autophagy-dependent degradation of HDAC proteins in sarcoma cells, as was previously observed in GI tumor cells, as well as the translocation of HDAC proteins from the nucleus to the cytosol. Our data would support the hypothesis that 602, acting as an HDAC inhibitor, would increase histone acetylation. Studies beyond the scope of the present manuscript will be required to completely understand how 602 regulates HDAC function and protein acetylation in tumor cells over hours and days.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this article are not readily available because the data is the property of Genzada and VCU. Requests to access the datasets should be directed to Paul Dent, paul.dent@vcuhealth.org.

**AUTHOR CONTRIBUTIONS**

LB performed the studies. DH and CW provided advice and research focus. PD wrote the manuscript. All authors contributed to the article and approved the submitted version.
Support for the present study was funded from Genzada Pharmaceuticals USA, Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

REFERENCES
1. Vishwakarma V, New J, Kumar D, Snyder V, Arnold L, Nissen E, et al. Potent antitumor effects of a combination of three nutraceutical compounds. Sci Rep. (2018) 8:12163. doi: 10.1038/s41598-018-29683-1
2. Booth L, Roberts JL, West C, Von Hoff D, Dent P. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy. J Cell Physiol. (2020). doi: 10.1002/jcp.29464. [Epub ahead of print].
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. (2015) 65:5–29. doi: 10.3322/caac.21234
4. Feinberg A, Pellecchia M, Onofre J, Heim J, Hzer N. Basic knowledge in soft tissue sarcoma. Cardiovasc Intervent Radiol. (2019) 42:1255–61. doi: 10.1007/s00270-019-02259-w
5. Andersen S, Mann H, Krarup-Ansens A, Lajer CR, Gronhøj C. Patient and tumour characteristics of adult head and neck soft tissue sarcomas: a systematic review and meta-analysis. Sarcoma. (2019) 9725637. doi: 10.1155/2019/9725637
6. Wilding CP, Elms ML, Judson I, Tan AC, Jones RL, Huang PH. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Rev Anticancer Ther. (2019) 19:971–91. doi: 10.1080/14737140.2018.1668979
7. Booth L, Roberts JL, Poklepovic A, Dent P. https://www.ncbi.nlm.nih.gov/pubmed/31380285 the lethality of [paazopanib + hdac inhibitors] is enhanced by neratinib. Front Oncol. (2019) 9:650. doi: 10.3389/fonc.2019.00650
8. Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, et al. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. (2017) 8:16367–86. doi: 10.18632/oncotarget.14829
9. Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, et al. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget. (2016) 7:12975–96. doi: 10.18632/oncotarget.7349
10. Tavallai S, Hamed HA, Grant S, Poklepovic A, Dent P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biol Ther. (2014) 15:157–88. doi: 10.4161/cbt.28163
11. Striifer FK, Brandes F, Baur A, Pfitzer BM, Kaul D, Rau D, et al. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience. BMC Cancer. (2020) 20:68. doi: 10.1186/s12885-020-6551-y
12. Vornicova O, Haim N, Bar-Sela G. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma. Cancer Chemother Pharmacol. (2019) 84:919–23. doi: 10.1007/s00280-019-03928-w
13. Salimina A, Kauppinen A, Kaarmiranta K. AMPK/Snfl signaling regulates histone acetylation: impact on gene expression and epigenetic functions. Cell Signal. (2016) 28:887–95. doi: 10.1016/j.cellsig.2016.03.009
14. McGee SL, van Denderen BJ, Howlett KF, Mollica J, Schertzer JD, Kemp BE, et al. AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes. (2008) 57:860–7. doi: 10.2337/db07-0843
15. Wu W, Luo M, Li K, Dai Y, Yi H, Zhong Y, et al. Cholesterol derivatives induce dephosphorylation of the histone deacetylases Rpd3/HDAC1 to upregulate autophagy. Autophagy. (2020) 1–17. doi: 10.1007/15548627.2020.1725376
16. Booth L, Roberts JL, Poklepovic A, Hancock JF. Curcumin-sildenafil enhances the efficacy of SFU and anti-PD1 therapies in vivo. Cell Physiol. (2020). doi: 10.1002/cip.29580. [Epub ahead of print].
17. Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, et al. The atafinib resistance of in vivo generated H1975 lung cancer cells is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. (2016) 7:19620–30. doi: 10.18632/oncotarget.7746
18. Booth L, Roberts JL, Tavallai M, Chukalakov J, Stringer DK, Koromilas AE, et al. https://www.ncbi.nlm.nih.gov/pubmed/27015562 + Sorafenib lethality is increased by inhibition of ERBB1/2/3-PJ1K-NFkB compensatory survival signaling. Oncotarget. (2016) 7:23608–32. doi: 10.18632/oncotarget.8281
19. Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, et al. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD1 immunomodulatory antibody in vivo. Oncol Res. (2017) 8:99451–69. doi: 10.18632/oncotarget.19807
20. Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, et al. The atafinib resistance of in vivo generated H1975 lung cancer cells is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. (2016) 7:19620–30. doi: 10.18632/oncotarget.7746
21. booth L, Roberts JL, Tavallai M, Chukalakov J, Stringer DK, Koromilas AE, et al. https://www.ncbi.nlm.nih.gov/pubmed/27015562 + Sorafenib lethality is increased by inhibition of ERBB1/2/3-PJ1K-NFkB compensatory survival signaling. Oncotarget. (2016) 7:23608–32. doi: 10.18632/oncotarget.8281
22. Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, et al. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD1 immunomodulatory antibody in vivo. Oncol Res. (2017) 8:99451–69. doi: 10.18632/oncotarget.19807
23. Boeira JM, Viana AF, Picana JN, Henriques JA. Genotoxic and recombinogetic activities of the two beta-carboline alkaloids harmar and harmine in Saccharomyces cerevisiae. Mutat Res. (2002) 509:39–48. doi: 10.1016/S0168-2677(01)00294-9
24. Ma Y, Wink M The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. (2010) 24:146–9. doi: 10.1002/ptr.2860
25. Song Y, Keshuma D, Wang J, Deng Y, Duan J, Wang JH, et al. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun. (2004) 317:128–32. doi: 10.1016/j.bbrc.2004.03.019
26. Khromov-Borisov NN, Picana JN, Henriques JA. Dose finding in the Ames Salmonella assay. Mutat Res. (2000) 453:35–44. doi: 10.1016/S0168-2677(00)00737-7

Conflict of Interest: PD has received funding support from Genzada Pharmaceuticals Inc. for these studies. CW is a paid officer of the company. DH is a paid consultant and a Key Scientific advisor to the company. PD is a paid consultant and a Key Advisor for Genzada Pharmaceuticals.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Booth, West, Hoff and Dent. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.